Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Nathan Fowler(Repligen (United States)), Catherine Thiéblemont(Université Paris Cité), Jason Butler(Oslo University Hospital), P. Joy Ho(The University of Sydney), Ram Malladi(Cambridge University Hospitals NHS Foundation Trust), Koji Kato(AbbVie (United States)), Andreas Petzer(Ordensklinikum Linz Barmherzige Schwestern), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Marie José Kersten(Hovon), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Bastian von Tresckow(University of Cologne), Takanori Teshima(Hokkaido University Hospital), Andy I. Chen(Scripps Research Institute), Monalisa Ghosh(Michigan Medicine), Piers Patten, Martin Dreyling(LMU Klinikum), Joseph P. McGuirk(University of Kansas Medical Center), Emmanuel Bachy(Université Claude Bernard Lyon 1), Aisha Masood(Novartis (United States)), Andreas Viardot(University Hospital Ulm), Charalambos Andreadis(University of California, San Francisco), Aiesha Zia(Novartis (Switzerland)), Stephen J. Schuster(Hospital of the University of Pennsylvania), Hideo Harigae(Tohoku University Hospital), Oezlem Anak(Novartis (Switzerland)), Julio C. Chávez(Moffitt Cancer Center), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Josè Antonio Pérez-Simón(Instituto de Biomedicina de Sevilla), Arne Kolstad(Oslo University Hospital), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Michael Dickinson(The University of Melbourne), Rakesh Awasthi(Novartis (Switzerland)), Leslie Popplewell(City Of Hope National Medical Center), Fritz Offner(Ghent University Hospital), Peter A. Riedell(University of Chicago)
Cited by 523
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k